Everything below concerns Melanotan II. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
== History == At the initiative of Sudameris, a French-Italian bank that served markets in South America, which had accumulated a large coffee surplus in its warehouses, Nestlé began developing a new instant coffee product in 1932 to use the surplus of beans. The large supply of surplus came from the lowered coffee prices in Brazil which resulted from the Wall Street Crash of 1929. Max Morgenthaler led the development project of the instant coffee product, which initially used spray drying to create the product from liquid coffee. Nestlé introduced the new product under the brand name "Nescafé" on April 1, 1938. It became an American staple during World War II.
Just as the action to change basal rate should be gradual in nature, the actual response from changing basal rate does not happen instantly. A change in basal rate is felt around two hours after the action is done. This is especially important for those with diabetes to note, as it affects when they should act to monitor their basal rates. For example, if there is a particular time in the day when one notices a problem with blood glucose levels, they should act to change their basal rate accordingly two hours prior to when the problem was previously experienced.
Hormonal IUDs (referred to as intrauterine systems in the UK) work by releasing a small amount of levonorgestrel, a progestin. The progestin released by hormonal IUDs primarily acts locally within the uterus, resulting in much lower systemic progestin levels than other progestogen only contraceptives. Each type of hormonal IUD varies in size, amount of levonorgestrel released, and duration of effectiveness. The predominant mechanism of action of progestin in the uterus is thickening the cervical mucus to prevent sperm from reaching the fallopian tubes and ultimately the egg. Hormonal IUDs can also thin the endometrial (uterine) lining and potentially impair implantation, but this is not their usual function. Because they thin the endometrial lining, hormonal IUDs often reduce or entirely stop menstrual bleeding. As a result, they are often used to treat menorrhagia (heavy menses), once pathologic causes of menorrhagia (such as uterine polyps) have been ruled out.
Sources: en.wikipedia.org
Only in 1901, when the Austrian Karl Landsteiner discovered three human blood groups (O, A, and B), did blood transfusion achieve a scientific basis and become safer. Landsteiner discovered that adverse effects arise from mixing blood from two incompatible individuals. He found that mixing incompatible types triggers an immune response and the red blood cells clump. The immunological reaction occurs when the receiver of a blood transfusion has antibodies against the donor blood cells. The destruction of red blood cells releases free hemoglobin into the bloodstream, which can have fatal consequences. Landsteiner's work made it possible to determine blood group and allowed blood transfusions to take place much more safely. For his discovery he won the Nobel Prize in Physiology and Medicine in 1930; many other blood groups have been discovered since. George Washington Crile is credited with performing the first surgery using a direct blood transfusion in 1906 at St. Alexis Hospital in Cleveland while a professor of surgery at Case Western Reserve University. Jan Janský also discovered the human blood groups; in 1907 he classified blood into four groups: I, II, III, IV. His nomenclature is still used in Russia and in states of the former USSR, in which blood types O, A, B, and AB are respectively designated I, II, III, and IV. American physician William Lorenzo Moss's (1876–1957) developed a blood typing technique in 1910 (popularly known as Moss system of blood typing) that was widely used until World War II.
cell surface receptor Any of a class of receptor proteins embedded within or attached to the external surface of the cell membrane, with one or more binding sites facing the extracellular environment and one or more effector sites that couple the binding of a particular ligand to an intracellular event or process. Cell surface receptors are a primary means by which environmental signals are received by the cell and transmitted across the membrane into the cell interior. Some may also bind exogenous ligands and transport them into the cell in a process known as receptor-mediated endocytosis.
As a result of the party's shift, Labour Party leader Neil Kinnock made a public attack against the entryist group Militant at the 1985 Labour Party conference in Bournemouth. The Labour Party ruled that Militant was ineligible for affiliation with the Labour Party and the party gradually expelled Militant supporters. The Kinnock leadership had refused to support the 1984–1985 miner's strike over pit closures, a decision that the party's left-wing and the National Union of Mineworkers blamed for the strike's eventual defeat.
Sources: en.wikipedia.org
Unlike the fast integration and intermarriages of creoles with Africans and Hispanics in Belize City, the creoles in the Belize river valley area had a lighter complexion and more visible European traits. The Belizean Creole along with Africans and Garifuna make up the Afro-Belizean population; about 30% of the population. The Creoles have had a great impact in Belizean history and politics. They were active and part of the Battle of St George's Caye, Part of the British West Indies Battalion in world war one and world war two, and the Negro movement for equal rights. They were one of the first group of people to advocate for and get a higher education in Jamaica and the UK in which after returning to Belize, the educated scholars rallied and started the movement for adult suffrage, self-government and independence. All of the important historical events started in Belize City and most of the first people involved were of creole descent which were the upper and middle class of Belize at the time. Well known Creole Belizeans were Samuel Haynes, Philip Goldson, Dean Barrow, Dame Minita Gordon, Cleopatra White, Cordel Hyde and Patrick Faber among others. The Creole were the biggest ethnic group in Belize until the 1980s due to mass migration of Afro Belizeans to the United States, United Kingdom and West Indies from the 1960s to 1970s and the mass immigration of Central American refugees to Belize. Due to the Central American War, and political instability, the country's demographics changed forever.
== Fragrance == Sandalwood oil is used extensively for its woody-floral scent. Sandalwood oil can also, under certain conditions, have a creamy or even pickled aroma. It pairs well with other wood or floral scents such as violet, rose, tuberose, clove, and oakmoss. But since the wood is so rare and expensive, cosmetic companies use synthetic substitutes of similar structure and scent. There are several synthetic odorants with odor similar to sandalwood oil, used as lower-cost alternatives for perfumes, emollients, and skin cleaning agents. Common synthetic substitutes include Bacdanlol, Brahmanol, Ebanol, Firsantol, Sandalore, and Sandaxol. Two of these, Sandalore and Brahmanol, have been found to be agonists of the cutaneous olfactory receptor OR2AT4, with potential therapeutic benefits for wound healing. Natural sandalwood oil, and other synthetic sandalwood odorants, did not have the same effect.
=== Hydroxykynureninuria === Also known as kynureninase deficiency, this extremely rare inherited disorder is caused by the defective enzyme kynureninase which leads to a block in the pathway from tryptophan to nicotinic acid mononucleotide (NaMN). As a result, tryptophan is no longer a source of niacin, hence not producing NAD, leading to pellagra (niacin deficiency). Both B6-responsive and B6-unresponsive forms are known. Patients with this disorder excrete excessive amounts of xanthurenic acid, kynurenic acid, 3-hydroxykynurenine, and kynurenine after tryptophan loading and are said to suffer from tachycardia, irregular breathing, arterial hypotension, cerebellar ataxia, developmental retardation, coma, renal tubular dysfunction, renal or metabolic acidosis, and even death. The only biochemical abnormality noted in affected patients was a massive hyperkynureninuria, seen only during periods of coma or after intravenous protein loading. This disturbance was temporarily corrected by large doses of vitamin B6. The activity of kynureninase in the liver was markedly reduced. The activity was appreciably restored by the addition of pyridoxal phosphate.
Arabic, the second language of Somalia, is spoken by a million or two million Somalis. This is because of longstanding ties with the Arab world, the influence of Arabic media, and religious education. It is a liturgical language as the language of the Qur'an. Somalis learn Arabic from a young age with an estimated 75 percent of children being able to read and write Arabic when they join formal schools at age six to eight years. English is widely spoken and taught due to colonial legacies and globalisation. Italian was official in Italian Somaliland, but significantly diminished following independence. Other languages include Bravanese, spoken by the Bravanese people, and Kibajuni of the Bajuni people.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.